Epigenetic Therapies in Oncology Analytical Tool 2022: The Must have Handbook for Any Business Developer, BI/CI Operative or Clinical Developer
July 22, 2022 04:08 ET
|
Research and Markets
Dublin, July 22, 2022 (GLOBE NEWSWIRE) -- The "Epigenetic Therapies in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. In cancer, many aspects of the...
The Worldwide Epigenetics Industry is Expected to Reach $2.9 Billion by 2028
June 16, 2022 05:43 ET
|
Research and Markets
Dublin, June 16, 2022 (GLOBE NEWSWIRE) -- The "Global Epigenetics Market Size, Share & Industry Trends Analysis Report By Application (Oncology and Non-Oncology), By Product, By End User, By...
Molecular Biology Enzymes, Kits, and Reagents Market Worth $41.10Bn, Globally, by 2028 at 17.8% CAGR Lead by Kits & Reagents Segment: The Insight Partners
May 26, 2022 02:31 ET
|
The Insight Partners
New York, May 26, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Molecular Biology Enzymes, Kits, and Reagents Market Forecast to 2028 – COVID-19 Impact and Global...
Inherent Biosciences, Inc. Awarded NIH SBIR Phase I Grant to Commercialize Innovative Diagnosis of Non-Obstructive Azoospermia (The Most Severe Form of Sperm Dysfunction)
April 13, 2022 09:11 ET
|
Inherent Biosciences Inc
SALT LAKE CITY, April 13, 2022 (GLOBE NEWSWIRE) -- Inherent Biosciences, a biotechnology company pioneering epigenetic medicine, today announced an award from the National Institute of Child Health...
Epigenetics Global and Regional Market Analysis: A $14,311.1 Million Market by 2031, Growing at a CAGR of 17% During 2021-2031
February 21, 2022 04:08 ET
|
Research and Markets
Dublin, Feb. 21, 2022 (GLOBE NEWSWIRE) -- The "Epigenetics Market - A Global and Regional Analysis: Focus on Product, Mechanism, Technology, Application, End User, and Region - Analysis and...
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference
February 17, 2022 08:01 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference
February 08, 2022 08:00 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
December 15, 2021 08:31 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference
November 29, 2021 08:01 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Inherent Biosciences Launches Path Fertility - Epigenetic Sperm Quality Test (SpermQT)
October 18, 2021 09:12 ET
|
Inherent Biosciences Inc
SALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Inherent Biosciences, a molecular diagnostics company at the intersection of epigenetics and artificial intelligence (AI), today announced the...